Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Abstract: Recombinant modified vaccinia Ankara (MVA) vectors expressing equine influenza virus genes were constructed and evaluated for use in equine vaccination. Two strains of recombinant MVA, expressing either hemagglutinin (HA) or nucleoprotein (NP) genes were constructed. Each influenza virus gene was cloned from A/equine/Kentucky/1/81 (Eq/Ky) into an MVA construction plasmid, and was introduced to the deletion III locus of the wild type MVA genome by homologous recombination. Recombinant viruses were plaque purified, and antigen expression was confirmed by immunostaining. Two ponies were primed by vaccination with 50 microg HA-DNA and two ponies were vaccinated with 50 microg NP-DNA using the PowderJect XR research device. Six and 10 weeks later, ponies were immunized with 2 x 10(9) infectious units of recombinant MVA encoding the homologous influenza antigen, equally divided between intramuscular and intradermal sites in the neck. A marked rise in influenza virus-specific IgGa and IgGb serum antibody titers was detected following administration of MVA boosters with both HA and NP antigens. Influenza virus-specific lymphoproliferative responses and IFN-gamma mRNA production were also strongly elicited by both antigens. This study demonstrates the facility with which recombinant MVA viruses expressing defined pathogen genes can be constructed, and provides preliminary evidence of the immunogenicity and safety of these vectors in the horse.
Publication Date: 2004-03-11 PubMed ID: 15010222DOI: 10.1016/j.vetimm.2003.11.004Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- Non-U.S. Gov't
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research focuses on the development and evaluation of recombinant modified vaccinia Ankara (MVA) vectors for potential use in equine influenza vaccination. It reveals the successful construction of recombinant MVA vectors expressing horse influenza virus genes and their immunogenic impact on horses.
Methodology
- Two strains of recombinant MVA were constructed. These vectors were designed to express either hemagglutinin (HA) or nucleoprotein (NP) genes of the influenza virus.
- The influenza virus genes were cloned from the A/equine/Kentucky/1/81 (Eq/Ky) into an MVA construction plasmid. These cloned genes were introduced to the deletion III locus of the regular MVA genome through a process called homologous recombination.
- The recombinant viruses were then purified, and the successful expression of the intended antigens was confirmed by immunostaining.
Vaccination and Immunity Response Evaluation
- Two ponies were primed with the HA-DNA vaccine, and two others were vaccinated using the NP-DNA solution.
- The ponies were immunized with infectious units of the recombinant MVA six and ten weeks later. This was done at both intramuscular and intradermal sites in the pony’s neck.
- A marked rise in the pony’s influenza virus-specific IgGa and IgGb serum antibody titers was observed after administering MVA boosters with both HA and NP antigens.
- A strong response from the influenza virus-specific lymphoproliferative system and IFN-gamma mRNA production was also observed as a response to both antigens.
Conclusions
- The study demonstrated the successful construction of recombinant MVA vectors expressing defined pathogen genes.
- Preliminary evidence shows that these vectors are immunogenic, invoking a physiological response from the ponies immune systems. This validates their potential use in equine influenza vaccination.
- The used method also guarantees safety during the vaccination process.
In conclusion, the research provides a robust foundation for using recombinant MVA vectors in equine influenza vaccination, showcasing their efficiency in invoking the desired immune response in horses.
Cite This Article
APA
Breathnach CC, Rudersdorf R, Lunn DP.
(2004).
Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Vet Immunol Immunopathol, 98(3-4), 127-136.
https://doi.org/10.1016/j.vetimm.2003.11.004 Publication
Researcher Affiliations
- Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA.
MeSH Terms
- Animals
- Antibodies, Viral / blood
- Base Sequence
- Enzyme-Linked Immunosorbent Assay / veterinary
- Genetic Vectors / genetics
- Genetic Vectors / immunology
- Horse Diseases / immunology
- Horse Diseases / prevention & control
- Horse Diseases / virology
- Horses
- Influenza A virus / genetics
- Influenza A virus / immunology
- Interferon-gamma / chemistry
- Interferon-gamma / genetics
- Male
- Molecular Sequence Data
- Orthomyxoviridae Infections / immunology
- Orthomyxoviridae Infections / prevention & control
- Orthomyxoviridae Infections / veterinary
- Orthomyxoviridae Infections / virology
- RNA, Messenger / chemistry
- RNA, Messenger / genetics
- Reassortant Viruses / immunology
- Reverse Transcriptase Polymerase Chain Reaction / veterinary
- Sequence Analysis, DNA
- Vaccination / methods
- Vaccination / veterinary
- Vaccines, DNA / genetics
- Vaccines, DNA / immunology
- Vaccines, DNA / therapeutic use
- Vaccinia virus / genetics
- Viral Vaccines / genetics
- Viral Vaccines / immunology
- Viral Vaccines / therapeutic use
Citations
This article has been cited 8 times.- Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM. Equine Influenza Virus and Vaccines.. Viruses 2021 Aug 20;13(8).
- Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies.. Front Microbiol 2018;9:1941.
- Hussey GS, Goehring LS, Lunn DP, Hussey SB, Huang T, Osterrieder N, Powell C, Hand J, Holz C, Slater J. Experimental infection with equine herpesvirus type 1 (EHV-1) induces chorioretinal lesions.. Vet Res 2013 Dec 5;44(1):118.
- Quinn K, Quirion MR, Lo CY, Misplon JA, Epstein SL, Chiorini JA. Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response.. Mol Ther 2011 Nov;19(11):1990-8.
- Soboll Hussey G, Hussey SB, Wagner B, Horohov DW, Van de Walle GR, Osterrieder N, Goehring LS, Rao S, Lunn DP. Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant.. Vet Res 2011 Feb 7;42(1):23.
- Berry JD, Hay K, Rini JM, Yu M, Wang L, Plummer FA, Corbett CR, Andonov A. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.. MAbs 2010 Jan-Feb;2(1):53-66.
- Chiam R, Sharp E, Maan S, Rao S, Mertens P, Blacklaws B, Davis-Poynter N, Wood J, Castillo-Olivares J. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).. PLoS One 2009 Jun 22;4(6):e5997.
- Mealey RH, Stone DM, Hines MT, Alperin DC, Littke MH, Leib SR, Leach SE, Hines SA. Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.. Vaccine 2007 Oct 23;25(43):7582-97.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
